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Background: Recent reports have shown that t-DARPP (truncated isoform of DARPP-32) can mediate trastuzumab
resistance in breast cancer cell models. In this study, we evaluated expression of t-DARPP in human primary breast
tumors, and investigated the role of t-DARPP in regulating growth and proliferation in breast cancer cells.
Results: Quantitative real time RT-PCR analysis using primers specific for t-DARPP demonstrated overexpression of
t-DARPP in 36% of breast cancers (13/36) as opposed to absent to very low t-DARPP expression in normal breast
tissue (p < 0.05). The mRNA overexpression of t-DARPP was overwhelmingly observed in ductal carcinomas,
including invasive ductal carcinomas and intraductal carcinomas, rather than other types of breast cancers. The
immunohistochemistry analysis of DARPP-32/t-DARPP protein(s) expression in breast cancer tissue microarray that
contained 59 tumors and matched normal tissues when available indicated overexpression in 35.5% of primary
breast tumors that were more frequent in invasive ductal carcinomas (43.7%; 21/48). In vitro studies showed that
stable overexpression of t-DARPP in MCF-7 cells positively regulated proliferation and anchorage-dependent and
-independent growth. Furthermore, this effect was concomitant with induction of phosphorylation of AKT
ser473 and
its downstream target phospho
ser9 GSK3b, and increased Cyclin D1 and C-Myc protein levels. The knockdown of
endogenous t-DARPP in HCC1569 cells led to a marked decrease in phosphorylation of AKTs
ser473 and GSK3b
ser9.
The use of PI3K inhibitor LY294002 or Akt siRNA abrogated the t-DARPP-mediated phosphorylation of AKT
ser473 and
led to a significant reduction in cell growth.
Conclusions: Our findings underscore the potential role of t-DARPP in regulating cell growth and proliferation
through PI3 kinase-dependent mechanism.
Background
Breast cancer is a leading cause of death among women
worldwide [1]. Identification of novel molecular targets
and studies of signaling pathways that drive breast can-
cer tumorigenesis hold the premise for improvement of
our current limited preventive, diagnostic, and therapeu-
tic capabilities to breast malignancies. There is clear evi-
dence that dysregulation of the PI3K/AKT signaling
plays a central role in the pathogenesis of breast cancer
[2-4]. The PI3K/AKT signaling regulates fundamental
cellular processes linked to tumorigenesis, including cell
growth, survival with resistance to therapy [3,5,6].
Recent studies have implicated activation of the PI3K/
AKT pathway in conferring resistance to conventional
chemotherapy and several chemotherapeutic agents (5-
fluorouracil, adriamycin, mitomycin C, and cisplatinum)
on cancer cells [7]. Somatic gain-of-function mutations
of PIK3CA are associated with an increased activation of
PI3K in breast cancers [8-10]. Functional analyses have
revealed that they increase enzymatic activity, induce
AKT signaling, and promote growth factor-independent
growth as well as increase cell invasion and metastasis
[11-13].
PPP1R1B, also known as dopamine and cyclic AMP
(c-AMP)-regulated phosphoprotein of Mr 32,000
(DARPP-32), mainly expressed in the brain, is involved
in dopaminergic neurotransmission and is a key factor
in the functioning of dopaminoceptive neurons [14]. A
comprehensive molecular analysis involving physical
mapping strategies of transcripts in the ERBB2 amplicon
region (17q12) pointed to the importance of EST
AA552509 as the critical target [15,16]. Further studies
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extension of cDNA ends) identified two transcripts [16].
The first transcript matched to DARPP-32. The second
transcript was a transcriptional splice variant of DARPP-
32 that encodes a truncated protein isoform that was
named t-DARPP. t-DARPP lacks the NH2-terminal pro-
tein phosphatase inhibitory domain of DARPP-32,
which is critical for dopamine signaling function in the
brain, and is frequently overexpressed in several com-
mon adenocarcinomas, such as those of the stomach,
colon, ovary and prostate [17-22]. In a previous study,
we have demonstrated that t-DARPP can mediate the
therapeutic resistance to trastuzumab through activation
of the AKT pathway in breast cancer cells [23]. In this
report, we have evaluated t-DARPP expression in
human primary breast tumors, and investigated the role
of t-DARPP in regulating cell growth and proliferation
in breast cancer cells.
Results
Overexpression of t-DARPP in primary breast tumors
We evaluated the mRNA expression of t-DARPP in 36
mRNA samples from primary breast tumors by quanti-
tative real-time PCR using primers that can specifically
detect t-DARPP unique sequence of the 5′ UTR of exon
1. In addition, we analyzed 18 normal adjacent breast
tissue samples for t-DARPP mRNA expression. The
results were normalized to HPRT1 as a stable reference
gene for quantitative real-time PCR. We detected over-
expression of t-DARPP in 36% of breast cancers relative
to normal breast tissues (p < 0.05) (Figure 1A). The
mRNA expression of t-DARPP was absent to very low
in normal breast tissue samples (Figure 1A). Based on
the histological tumor type information, we found that
the mRNA overexpression of t-DARPP was overwhel-
mingly observed in ductal carcinomas, including invasive
ductal carcinomas and intraductal carcinomas, rather
than other types of breast cancers (p = 0.06) (Figure
1B). The other types of breast cancers included 1 inva-
sive lobular carcinoma, 1 mucinous carcinoma, 1 apoc-
rine carcinoma, and 3 undifferentiated carcinomas.
We have attempted to evaluate the protein expression
of t-DARPP in primary breast tumors by Immunohisto-
chemistry analysis (IHC). As a specific antibody that
exclusively detects t-DARPP was not available, we initi-
ally used the C-terminal DARPP-32 antibody (H-62;
Santa Cruz Biotechnology), which detects both t-DARPP
and DARPP-32 proteins, for immunohistochemical stain-
ing on tissue microarrays containing 59 primary breast
tumor samples (FULL MOON Biosystems & AccuMax
Array). IHC analysis of DARPP-32/t-DARPP proteins in
breast tumor tissue samples indicated expression in both
nucleus and cytoplasm with nuclear staining frequently
stronger than cytoplasm staining [Additional file 1: Sup-
plemental Figure S1]. Overall, our results indicated that
high DARPP-32/t-DARPP expression scores (3+) were
Figure 1 t-DARPP is overexpressed in primary breast tumors. A, normal adjacent (n = 18) and tumor (n = 36) breast tissue samples were
analyzed by quantitative real time RT-PCR for t-DARPP mRNA expression. RT-PCR results were normalized with the internal control genes b-actin
and HPRT1. The results were plotted as a ratio of normalized t-DARPP mRNA expression by the average of normalized t-DARPP mRNA expression
of normal samples. Overexpression of t-DARPP was detected in 36% of breast tumors relative to normal tissue samples (p < 0.05). B, the
overexpression of t-DARPP was overwhelmingly observed in ductal carcinomas (p = 0.06), including invasive ductal carcinomas and intraductal
carcinomas, as opposed to other types of breast cancers. The other types of breast cancers include 1 invasive lobular carcinoma, 1 mucinous
carcinoma, 1 apocrine carcinoma and 3 undifferentiated carcinomas. Horizontal bars indicate mean values. Mann Whitney test was used for
statistical analysis in A and B.
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of normal tissue samples [Additional file 2: Supplemental
Table S1]. The difference in DARPP-32/t-DARPP expres-
sion between normal tissue and tumor samples was sta-
tistically significant (p < 0.01). Based on the clinical
information provided with the tissue microarrays, we
found a statistically significant difference (p = 0.022)
between DARPP-32/t-DARPP expression scores and his-
tological tumor types (invasive ductal carcinoma or
other). Our results indicated that 21 (43.7%) out of 48
invasive ductal carcinoma samples exhibited high (3+)
DARPP-32/t-DARPP expression, the other histological
carcinomas displayed absent or much lower expression
[Additional file 2: Supplemental Table S1].
In an attempt to discriminate between the protein
expression of DARPP-32 and t-DARPP, we performed
immunohistochemical staining on duplicate TMA slides
containing 19 primary breast tumor samples (AccuMax
Array). We used the C-terminal DARPP-32 antibody
(H-62; Santa Cruz Biotechnology), which detects both t-
DARPP and DARPP-32 proteins, and the N-terminal
DARPP-32 monoclonal antibody (EP720Y; abcam),
which exclusively detects DARPP-32 protein. The results
indicated that the immunostaining with C-terminal
DARPP-32 antibody was relatively higher in 8 (42.1%)
tumor samples than N-terminal DARPP-32 antibody. In
contrast, only one (5.2%) tumor sample showed more
immunostaining with N-DARPP-32 antibody [Additional
file 3: Supplemental Table S2]. In fact, among the 8
tumor samples showing higher C-DARPP-32 IHC
scores, 4 samples were completely negative for N-
DARPP-32 immunostaining. These results suggested
that protein expression of t-DARPP was higher than
DARPP-32 in these analyzed primary breast tumor
samples.
Ectopically expressed t-DARPP promotes anchorage-
dependent and anchorage-independent cell growth
To investigate the effect of ectopic t-DARPP overexpres-
sion on cell growth, we developed a cell model by stably
expressing t-DARPP or pcDNA3.1 empty vector in MCF-
7 cells, which are negativef o re n d o g e n o u st - D A R P P
expression. The cells were grown for several days and
then subjected to Cell Titer-Glo Luminiscent Cell Viabi-
lity assay. Our results confi r m e dt h a tt - D A R P Pe c t o p i c
expression in MCF-7 cells significantly enhanced cell
growth starting at day 1 and reaching approximately 44%
growth increase relative to control cells at day 4 (p <
0.0001) (Figure 2A). To confirm that t-DARPP-induced
cell growth results were not affected by apoptosis as a
result of growth conditions, we subjected protein extracts
from a similar cell growth experiment to western blot
analysis of Caspase-7, PARP, and t-DARPP. Indeed, the
results showed that the experimental growth conditions
did not induce significant apoptosis as indicated by Cas-
pase-7 and PARP protein levels (Figure 2B). To ascertain
that t-DARPP-induced cell growth was due to increased
proliferation, we subjected MCF-7/pcDNA3.1 and MCF-
7/t-DARPP cells that were grown for 48 h to the Click-iT
EdU cell proliferation assay (Invitrogen). The proliferat-
ing cells were positive for EdU signal as depicted by
green fluorescence, and all the proliferating and non-pro-
liferating cells were counterstained with DAPI (blue
nuclear fluorescence) (Figure 2C). The results indicated
that cell proliferation of t-DARPP-expressing cells (37%)
was significantly higher than control cells (16%, p < 0.01)
(Figure 2D). These findings clearly showed that t-DARPP
expression promotes cell proliferation in breast cancer
cells.
Anchorage-independent growth capability is one of
the hallmarks of oncogenically transformed cells.
Furthermore, increased anchorage-independent growth
may potentially indicate enhanced cell tumorigenicity in
vivo. To investigate the role of t-DARPP in regulating
anchorage-independent growth in breast cancer cells, we
examined colony formation on soft agar using the MCF-
7/t-DARPP cell model described above. The results
showed that t-DARPP-expressing cells produced mark-
edly higher number of colonies (>4-fold increase, p <
0.001) than control cells (Figure 3A &3B). This
enhanced anchorage-independent growth capability of t-
DARPP-expressing MCF-7 cells was associated with
increased p-AKT
ser473 and p-GSK3b
ser9 protein levels as
compared with control cells (Figure 3C). In addition, we
examined the expression of b-catenin downstream
signaling effectors Cyclin D1 and C-Myc, and found a
significant increase of their protein levels in t-DARPP-
expressing cells as compared with control cells (Figure
3C). These results suggest that t-DARPP regulates AKT
signaling in vitro.
Endogenous t-DARPP expression correlates with
activation of AKT signaling pathway in breast cancer cell
lines
As we have shown that ectopic t-DARPP expression was
associated with activation of the AKT pathway in MCF-
7 cell model (Figure 3C), we sought to determine if this
association was established in a panel of 8 additional
breast cancer cell lines. We have shown t-DARPP pro-
tein expression in multiple breast cancer cell lines by
western blot analysis as indicated by a specific 28 kDa
protein band (Figure 4A). Overall, our results indicated
that all the t-DARPP-expressing cells (MDA-MB-
175VII, HCC-1419, HCC-1599, and HCC-1569) exhib-
ited a significantly higher p-AKT
ser473 and p-GSK3b
ser9
protein levels as compared with t-DARPP-non-expres-
sing cell lines (MDA-MB-134VI, HCC-1428, and HCC-
1500) (Figure 4A). In contrast, HCC-1395 cells were the
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but showed high p-AKT
ser473 and p-GSK3b
ser9 protein
levels (Figure 4A). Interestingly, HCC-1395 cells were
reported to be negative for expression of PTEN, a nega-
tive regulator of PI3K/AKT pathway, as a result of a
homozygous PTEN deletion-frame-shift mutation (San-
ger Institute, UK), thus explaining the activation of the
AKT signaling pathway. Taken together, our results
showed a direct correlation between t-DARPP expres-
sion and activation of the AKT pathway in the tested
breast cancer cell lines.
To investigate the role of endogenous t-DARPP in
regulating the AKT pathway and cell growth, we
knocked down t-DARPP expression with siRNA in
HCC-1569 cells and then evaluated the AKT signaling
effectors by western blot analysis. In parallel, we deter-
mined the effect of t-DARPP knockdown on cell
growth using the Cell Titer-Glo Luminescent Cell Via-
bility Assay. The knockdown of endogenous t-DARPP
resulted in down-regulation of the AKT pathway as
indicated by decreased levels of p-AKT
ser473 and p-
GSK3b
ser9 proteins in HCC-1569 cells as compared
with control cells (Figure 4B). In addition, the results
showed that t-DARPP knockdown led to a marked
decrease (20%) in cell viability in HCC-1569 cells as
compared with cells transfected with control siRNA
(p < 0.01) (Figure 4C). Together, these findings sug-
gested that t-DARPP-dependent cell growth implicated
Figure 2 t-DARPP ectopic overexpression promotes breast cancer cell growth and proliferation. A, MCF-7 cells were stably transfected
with t-DARPP or pcDNA3.1 empty vector control plasmids. The cells (2 × 10
3 cells per well) were seeded onto 96-well culture plates and grown
for 1, 2, 3, and 4 days and then subjected to Cell Titer-Glo Luminiscent Cell Viability Assay. Growth rate of MCF-7 cells stably expressing t-DARPP
(grey color) was significantly higher (p < 0.0001) than empty vector control cells (black color). B, the cells (2 × 10
5 cells per well) were seeded
onto 6-well culture plates and grown for 1, 2, 3, and 4 days. Protein extracts from these cell cultures were subjected to western blot analysis of
t-DARPP, Caspase-7, PARP, and b-actin. The results indicated that t-DARPP-induced cell growth over 4 days was not affected by apoptosis as
shown by Caspase-7 and PARP. C, MCF-7/pcDNA3.1 and MCF-7/t-DARPP cells were grown for 48 h then subjected to the Click-iT EdU
proliferation Assay. Proliferating cells were depicted by EdU positive staining (green fluorescence) and all the cells were stained with DAPI
(nuclear blue fluorescence). D, a summary of the results showing the percent of proliferating cells. Cell proliferation of t-DARPP-expressing cells
(37%) was significantly higher than control cells (16%, p < 0.01). Results are representative of at least three experiments and shown as the mean
± SD. Significance of difference was calculated using Student’s t test.
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cer cells.
t-DARPP induces cell growth through PI3 kinase-
dependent mechanism
Our results demonstrated that t-DARPP-regulated cell
growth directly correlated with the activity of AKT
pathway as indicated by protein levels of p-AKT
ser473
and its downstream substrate p-GSK3b
ser9 in breast
cancer cells expressing ectopic or endogenous t-DARPP
protein (Figures 3 &4). To determine if t-DARPP-
induced cell growth was dependent on PI3K/AKT path-
way, we treated MCF-7/t-DARPP and MCF-7/
pcDNA3.1 cells with 40 μM of the PI3K specific phar-
macologic inhibitor LY294002 (Cell Signaling) or vehicle
( D M S O )f o r3 0m i no r2h ,a n dt h ec e l l sw e r eg r o w n
for an additional 24 h. The cells were then subjected to
Cell-Titer-Glo Luminescent Cell Viability Assay to
Figure 3 t-DARPP expression enhances anchorage-independent cell growth in soft agar. A, MCF-7 cells stably expressing t-DARPP or
pcDNA3.1 empty vector were seeded in soft agar onto 6-well tissue culture plates (10
5 cells per well). The cells were grown for one month to
allow for anchorage-independent colony formation. B, Quantification of colony formation indicated that MCF-7/t-DARPP cells produced markedly
higher number of colonies than control cells (>4-fold increase, p < 0.001). C, Protein extracts from MCF-7/t-DARPP and MCF-7/pcDNA3.1 cells
were analyzed by western blot for t-DARPP, p-AKT (S473), AKT, p-GSK3b (S9), GSK3b, C-Myc, Cyclin D1, and b-actin. t-DARPP expression directly
correlated with increased phospho-AKT
ser473, phospho-GSK3b
ser9, C-Myc, and Cyclin D1 protein levels. Results are representative of at least three
experiments and shown as the mean ± SD. Significance of difference was calculated using Student’s t test analysis.
Figure 4 t-DARPP expression directly correlates with activation of AKT pathway in breast cancer cell lines, and knockdown of
endogenous t-DARPP suppresses cell growth. A, Protein extracts from a panel of 8 breast cancer cell lines were subjected to western blot
analysis of t-DARPP, p-AKT
ser473, AKT, p-GSK3b
ser9, GSK3b, and b-actin. 10 μg of total protein per lane were resolved on 10% SDS-PAGE and
transferred onto Hybond-P PVDF membranes for immunodetection with the corresponding specific antibodies. B&C, HCC-1569 cells were
transfected with control scrambled siRNA or t-DARPP siRNA oligonucleotides and grown for 48 h. Protein extracts were subjected to western
blot analysis of t-DARPP, p-AKT
ser473, AKT, p-GSK3b
ser9, and GSK3b (panel B). Knockdown of t-DARPP in HCC-1569 cells led to down-regulation of
the AKT signaling pathway as indicated by a significant decrease of p-AKT
ser473 and p-GSK3b
ser9 protein levels. The cells were subjected to Cell-
Titer-Glo Luminescent Cell Viability Assay. Overall, cell growth was significantly lower in HCC-1569 cells transfected with t-DARPP siRNA than
control cells (panel C). Results are representative of three experiments and shown as the mean ± SD. Significance of difference was calculated
using Student’s t test analysis.
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increase of growth (approximately 67%) in t-DARPP-
expressing cells relative to control cells after treatment
with vehicle (p < 0.0001) (Figure 5A). In contrast, treat-
ment with LY294002 inhibitor led to a significant aver-
age growth decrease of 36% (p < 0.001) relative to
treatment with vehicle in t-DARPP-expressing cells
(Figure 5A). In fact, the growth decrease (36%) resulting
from LY294002 treatment in t-DARPP-expressing cells
approximately accounted for the growth increase in
t-DARPP-expressing cells relative to control cells after
treatment with vehicle. Interestingly, treatment with
LY294002 led to a growth decrease of approximately
24% relative to vehicle in control cells as opposed to
36% in t-DARPP-expressing cells (Figure 5A). This indi-
cated that t-DARPP-expressing cells were more sensitive
to LY294002, and therefore to inhibition of PI3K/AKT
pathway, than control cells. Together, our results
showed that treatment with LY294002 inhibitor abro-
gated t-DARPP-induced cell growth in MCF-7 cells. In
addition, our western blot analysis results indicated that,
as expected, p-AKT
ser473 protein level was significantly
higher in t-DARPP-expressin gc e l l sa sc o m p a r e dw i t h
control cells following treatment with vehicle. In con-
trast, treatment with LY294002 inhibitor completely
blocked phosphorylation of AKT in all cells (Figure 5B).
These results clearly demonstrated that t-DARPP-
induced growth in MCF-7 cells was dependent on acti-
vation of PI3K/AKT pathway as inhibition of PI3K with
LY294002 led to almost complete abrogation of t-
DARPP function. To further confirm that t-DARPP-
induced cell growth was dependent on PI3K/AKT path-
way, we transfected MCF-7/t-DARPP and MCF-7/
pcDNA3.1 cells with Akt siRNA or control scrambled
siRNA oligonucleotides, and the cells were cultured for
48 h. The cells were then subjected to Cell-Titer-Glo
Luminescent Cell Viability Assay to measure cell
growth. The results indicated a significant increase of
growth (approximately 85%) in t-DARPP-expressing
cells relative to control cells transfected with control
scrambled siRNA (p < 0.0001) (Figure 5C). In contrast,
transfection with Akt siRNA led to a significant growth
decrease of 28.5% (p = 0.0001) relative to transfection
with control scrambled siRNA in t-DARPP-expressing
cells (Figure 5C). This growth decrease resulting from
AKT knockdown indicated a partial abrogation of the
growth increase of t-DARPP-expressing cells relative to
control cells. Our western blot analysis results clearly
indicated knockdown of AKT and p-AKT
ser473 after
transfecting cells with Akt siRNA oligonucleotide (Fig-
ure 5D). In summary, these results confirmed that t-
DARPP-induced growth in MCF-7 cells was dependent
on activation of PI3K/AKT pathway as inhibition of
PI3K with LY294002 or knocking down AKT with Akt
siRNA led to abrogation of t-DARPP cell growth
promoting function.
Discussion
In this study, we have demonstrated that t-DARPP regu-
lates cell growth and proliferation through activation of
PI3K/AKT pathway in human breast cancer cells. To
evaluate the specific expression of t-DARPP in breast
tissue samples, we employed real-time RT-PCR using
primers that can specifically detect t-DARPP unique
sequence of the 5′UTR region of exon 1. We have
shown for the first time that t-DARPP was overex-
p r e s s e da tt h em R N Al e v e li n3 6 %o fp r i m a r yb r e a s t
tumors relative to normal breast tissues (p < 0.05). In
addition, we demonstrated that the overwhelming
majority of samples that overexpressed t-DARPP were
ductal carcinomas as opposed to other carcinomas (p =
0.06). Although statistically not significant (p = 0.06),
the difference in t-DARPP expression level between duc-
tal carcinomas and other types of carcinomas indicated
a trend that could be confirmed by analyzing additional
tumor samples.
As an exclusively specific antibody for t-DARPP was
not available, we evaluated the expression of DARPP-
32/t-DARPP protein(s) in primary breast tumors by IHC
analysis using C-terminal DARPP-32 antibody. We
showed overexpression of DARPP-32/t-DARPP protein
(s) in 35.5% of tumors. While our finding is consistent
with a recent report [24], we demonstrated that high
l e v e lo fe x p r e s s i o no fD A R P P - 3 2 / t - D A R P Pp r o t e i n ( s )( 3
+) was exclusively seen in invasive ductal carcinomas
(IDC). This is an important observation since these
tumors are characterized by a poor prognosis [25,26].
IDC is a common type of breast cancer, which has the
potential to invade lymph nodes and blood systems, and
eventually metastasize to other parts of the body, sug-
gesting a possible role of DARPP-32/t-DARPP protein(s)
in tumor progression [27-29]. In an attempt to discrimi-
nate between DARPP-32 and t-DARPP protein expres-
sion, we performed IHC analysis on duplicate breast
tumor TMA with C-terminal DARPP-32 antibody,
which recognizes both DARPP-32 and t-DARPP pro-
teins, and N-terminal DARPP-32 antibody, which exclu-
sively detects DARPP-32 protein. The IHC results
indicated that 42.1% of tumors stained with both antibo-
dies. However, the immunostaining with C-terminal
DARPP-32 antibody was relatively higher than N-term-
inal DARPP-32 antibody. Half of these tumors were
exclusively positive for immunostaining with C-terminal
DARPP-32 antibody. These results suggested that t-
DARPP protein expression was predominant in breast
tumors as opposed to expression of DARPP-32 protein.
Therefore, the immunostaining with C-terminal
DARPP-32 antibody would mostly indicate the
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Page 6 of 11Figure 5 t-DARPP-induced cell growth is dependent on PI3K/AKT signaling pathway. A, MCF-7 cells stably expressing t-DARPP or pcDNA3.1
vector were treated with either vehicle or 40 μM of LY294002 for 30 min or 2 h. The cells were washed with PBS and grown for 24 h, and then
subjected to Cell-Titer-Glo Luminescent Cell Viability Assay. The results indicated a significant increase of cell growth in t-DARPP-expressing cells
relative to control cells after treatment with vehicle. This growth increase was almost completely abrogated after treatment with LY294002. B, MCF-
7/t-DARPP and MCF-7/pcDNA3.1 cells were treated with vehicle and 40 μM of LY294002 for 30 min or 2 h, and then grown for 24 h. Protein
extracts were subjected to western blot analysis of t-DARPP, p-AKT
ser473, and AKT. The results showed that p-AKT
ser473 protein level was significantly
higher in t-DARPP-expressing cells than control cells, and treatment with LY294002 blocked phosphorylation of AKT
ser473 in all cells. C, MCF-7/t-
DARPP and MCF-7/pcDNA3.1 cells were transfected with scrambled siRNA or Akt siRNA and grown for 48 h. The cells were then subjected to Cell-
Titer-Glo Luminescent Cell Viability Assay. The results indicated a significant increase of cell growth in t-DARPP-expressing cells relative to control
cells after transfection with scrambled siRNA. This growth increase was partially abrogated after transfection with Akt siRNA. D, MCF-7/t-DARPP and
MCF-7/pcDNA3.1 cells were transfected with scrambled siRNA or Akt siRNA and cultured for 48 h. Protein extracts were analyzed by Western blot
for p-AKT
ser473, AKT, t-DARPP, and b-actin. Results are representative of four experiments and shown as the mean ± SD. Significance of difference
was calculated using Student’s t test analysis.
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results showed that the frequency of t-DARPP mRNA
overexpression (36%) was comparable to that of high
DARPP-32/t-DARPP protein(s) expression (35.5%) in
primary breast tumors.
In this current study, we have clearly demonstrated
that endogenous and ectopically expressed t-DARPP
exhibited a novel biological function by enhancing cell
growth and proliferation in breast cancer cells. We have
confirmed that t-DARPP-induced cell growth was not
significantly affected by apoptosis in our in vitro MCF-7
cell model as indicated by Caspase-7 and PARP pro-
teins. Generally, in absence of chemotherapeutics, can-
cer cells have little apoptosis. Therefore, the
predominant function of t-DARRP in this case is to
induce cell growth. In addition, we have investigated the
role of t-DARPP in regulating anchorage-independent
cell growth, which is one of the hallmarks of oncogeni-
cally transformed cells, and enhanced anchorage-inde-
pendent growth capability may potentially increase cell
tumorigenicity. Indeed, we have shown that t-DARPP
expression significantly increased anchorage-indepen-
dent growth capability of MCF-7 cells.
As part of an attempt to identify the signaling pathway
that could be implicated in the regulation of t-DARPP-
induced cell growth, we confirmed a direct correlation
between expression of t-DARPP and activation of AKT
pathway as indicated by increased phospho-AKT
ser473
and phospho-GSK3b
ser9 protein levels in multiple breast
cancer cell lines. We have also shown that t-DARPP-
induced cell growth and proliferation were associated
with phosphorylation of GSK3b
ser9 and increased growth
signaling effectors C-Myc and Cyclin D1 protein levels.
The regulation of Cyclin D1 and C-Myc can be
mediated by b-catenin as well as other signaling
mechanisms. Future studies are required to fully eluci-
date the mechanism by which t-DARPP regulates C-Myc
and Cyclin D1 genes.
Several reports indicated that dysregulation of the
PI3K/AKT pathway plays a major role in the pathogen-
esis of breast cancer [2-4]. The PI3K/AKT signaling reg-
ulates cellular processes associated with breast
tumorigenesis, including survival and cell growth [2,3].
Recent reports suggested the role of t-DARPP in med-
iating trastuzumab resistance in vitro mainly through
modulation of the AKT signaling pathway in breast can-
cer cells [23,24,30]. In this study, we demonstrated that
t-DARPP-induced cell growth was regulated through
PI3K/AKT-dependent mechanism as inhibition of PI3
kinase with LY294002 and knocking down AKT with
siRNA significantly abrogated t-DARPP function. This
indicates that t-DARPP signaling to AKT is likely
upstream of PI3 Kinase. In addition, inhibition of PI3K
with LY294002 led to a substantial decrease of protein
levels C-Myc and Cyclin D1 in t-DARPP-expressing
cells (data not shown). Thiss u g g e s t st h a tt - D A R P P -
induced growth and proliferation is regulated by
t-DARPP-dependent activation of AKT and potentially
b-catenin signaling pathway.
In this report, we have shown that t-DARPP regulated
AKT pathway in ERBB2-positive cells (HCC-1569) and
ERBB2-negative cells (MCF-7). It is possible that t-
DARPP is involved in regulation of RTKs or PTEN that
are main drivers of PI3K/AKT activation [31-33].
Further studies are required to elucidate the potential
molecular mechanisms by which t-DARPP regulates
PI3K/AKT signaling in cancer cells. The t-DARPP-
induced anchorage-dependent and -independent cell
growth underscores the oncogenic properties of t-
DARPP whose overexpression may play an important
role in breast tumorigenesis. The results from our MCF-
7 cell model suggest that evaluation of t-DARPP mRNA
expression with quantitative real-time PCR in tumors
may prove useful for clinical management of breast can-
cer patients. For instance, as we have shown that t-
DARPP function was dependent on activation of PI3K/
AKT signaling, targeting AKT pathway or RTKs in can-
cer patients who overexpress t-DARPP could signifi-
cantly improve the treatment of breast cancer.
Conclusions
Our findings highlight the important role of t-DARPP in
breast tumorigenesis by regulation of cell growth and
proliferation through PI3K/AKT-dependent mechanism.
Further studies are necessary to explore the mechanism
by which t-DARPP regulates the PI3K/AKT signaling
pathway in breast cancer cells.
Methods
Cell lines and plasmids
The human breast cancer cell lines, SKBR-3, MCF-7,
MDA-MB-134VI, HCC-1428, HCC-1500, MDA-MB-
175VII, HCC-1395, HCC-1419, HCC-1599, and HCC-
1569 cells were obtained from the American Type Cul-
ture Collection (ATCC, Rockville, MD). All cells were
maintained in F12 medium supplemented with 10% fetal
bovine serum and 2 mM L-glutamine. The expression
plasmid for t-DARPP was prepared by PCR amplifica-
tion of the full-length coding sequence of t-DARPP
(accession no. AY070271) and cloned in-frame into
pcDNA3.1 (Invitrogen Life Technologies). MCF-7 stably
expressing t-DARPP or pcDNA3.1 empty vector were
generated following standard protocols as described pre-
viously [34]. After selection with 500 μg/ml neomycin
(G418) (Invitrogen Life Technologies), t-DARPP protein
expression was evaluated by western blot analysis.
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Quantitative real-time PCR was performed in triplicate
using an iCycler (Bio-Rad) with a threshold cycle num-
ber determined by use of iCycler software version 3.0.
Single-stranded cDNA was synthesized from a total
RNA amount of 1 μg using the Advantage Reverse
Transcription-PCR kit (Clontech). mRNA specific pri-
mers for t-DARPP, b-actin, and HPRT1 were designed,
and the results were normalized to HPRT1 as a stable
reference gene for quantitative real-time PCR. All pri-
mer sequences are available upon request. The mRNA
fold expression levels were calculated according to the
formula 2
(RT-ET)/2
(Rn-En), as described previously [16].
We used an arbitrary cutoff value of 2-fold as a mini-
mum for any overexpression.
Immunohistochemistry
Tissue microarrays (TMA) containing 59 de-identified,
archival cases of breast tumors, including 25 adjacent
“normal” breast tissue samples, were obtained from
FULL MOON Biosystems and AccuMax Array. All the
cases provided the information of the original pathology
diagnosis. 5 μM TMA sections were used for IHC stain-
ing of DARPP-32/t-DARPP using rabbit polyclonal
DARPP-32 antibody (Clone H-62; 1:200 dilution, Santa
Cruz Biotechnology, Inc., Santa Cruz, CA), which speci-
fically recognizes the C-terminal end of both DARPP-32
and t-DARPP proteins. A TMA containing 19 breast
tumors (AccuMax Array) was used for IHC staining
with the C-terminal DARPP-32 antibody (described
above) and rabbit monoclonal DARPP-32 antibody
(Clone EP720Y; 1:250 dilution, abcam Inc., Cambridge,
MA), which exclusively recognizes the N-terminal end
of DARPP-32 protein. De-waxing and rehydration by
descending concentrations of ethanol was followed by
antigen retrieval (20 minutes in a microwave, 450 W, 10
mM EDTA, pH 8.0). 10 minutes blocking was per-
formed with 10% goat serum in PBS. The sections were
incubated overnight with either C-terminal or N-term-
inal DARPP-32 primary antibody, followed by washing
in PBS and incubation with anti-rabbit secondary anti-
body for 1 hour at room temperature. The Vectastain
ABC-AP KIT (vector; Alexis, Gruenberg, Germany) was
used as the chromogen substrate, and the specimens
were counterstained with hematoxylin. Specificity of
immunostaining was checked by replacing the primary
antibody with non-immune serum. A known positive
breast cancer tissue slide was used as a positive control.
DARPP-32/t-DARPP expression level was estimated
semi-quantitatively [35]. Cores with torn tissues were
excluded from the analyses. Cores with no evidence of
nuclear or cytoplasmic staining, or only rare scattered
positive cells less than 3%, were recorded as negative.
The overall intensity of staining was recorded as that for
the core with the strongest intensity. Immunohisto-
chemical results were evaluated for intensity and
frequency of staining of nuclear and cytoplasmic com-
ponents and the whole. The intensity of staining was
graded as 0 (negative), 1 (weak), 2 (moderate), and 3
(strong). The frequency was graded from 0 to 4 by per-
centage of positive cells as follows: grade 0, <3%; grade
1, 3~25%; grade 2, 25~50%; grade 3, 50~75%; grade 4,
more than 75%. The index score was the product of
multiplication of the intensity and frequency grades,
which was then pinned into a 4 point scale: index score
0 = product of 0, index score 1 = products 1 to 4, index
score 2 = products 5 and 9, index score 3 = products 10
to 12.
Immunoblot analysis
Protein extracts (10 to 20 μg/lane) were resolved on 10%
SDS-PAGE and then transferred on Hybond-P PVDF
membranes (Amersham Biosciences), and subjected to
western blot analysis. Rabbit polyclonal DARPP-32 anti-
body (clone H-62; 1:1000 dilution), which recognizes the
C-terminal end of t-DARPP protein, and mouse mono-
clonal C-Myc antibody (Clone 9E10; 1:500 dilution)
were obtained from Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA. Mouse monoclonal AKT antibody
(Clone 40D4; 1:2000 dilution), which recognizes the C-
terminal end of AKT protein; rabbit polyclonal phos-
pho-AKT
ser473 antibody (1:1000 dilution); rabbit mono-
clonal GSK3b antibody (Clone 27C10; 1:1000 dilution);
rabbit monoclonal phospho-GSK3b
ser9 antibody (Clone
5B3; 1:1000 dilution); rabbit polyclonal Cyclin D1 anti-
body (1:1000 dilution); and rabbit polyclonal b-actin
antibody (1:1000 dilution) were obtained from Cell Sig-
naling Technology, Inc., Danvers, MA. Horseradish per-
oxidase-conjugated anti-mouse (1:5000 dilution) and
anti-rabbit (1:5000 dilution) secondary antibodies were
purchased from Santa Cruz Biotechnology and Cell Sig-
naling Technology, respectively. Immunoreactive protein
bands were visualized by enhanced chemiluminescence
(Pierce).
Cell viability/growth assay
Cells (2 × 10
3 per well) were seeded onto a 96-well
plate. The cell viability of these cells after knockdown of
endogenous t-DARPP or ectopic expression of t-DARPP
was determined using the Cell Titer-Glo Luminescent
Cell Viability Assay kit (Promega) following the supplier′
s instructions.
Cell proliferation assay
To measure cell proliferation, we have used the Click-iT
EdU Assay (Invitrogen), which is an alternative to the
BrdU assay. EdU (5-ethynyl-2′-deoxyuridine) is a nucleo-
side analog of thymidine and is incorporated into DNA
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3 per
chamber) were seeded onto 8-chamber slides and incu-
bated at 37°C in an atmosphere containing 5% CO2 for
48 h. For labeling cells with EdU, equal volume of 2 X
EdU solutions was added to the cells, and incubated at
37°C/5% CO2 for 60 min. The cells were then fixed with
3.7% formaldehyde in PBS at room temperature for 15
min, followed by permeabilization with 0.5% Triton X-
100 in PBS for 20 min at room temperature. In this
assay, detection of the signal is based on a click reaction,
a copper-catalyzed covalent reaction between the EdU
and the Alexa Fluor 488 dye. Click-iT reaction cocktail
w a sa d d e dt ot h ec e l l sa n di n c u b a t e df o r3 0m i na t
room temperature, and protected from the light. Follow-
ing removal of click-iT reaction cocktail, the cells were
washed twice with 1 ml 3% BSA in PBS. Prior to exami-
nation with fluorescence microscopy, Vectashield
mounting medium with 4′,6-diamidino-2-phenylindole
(DAPI) (Vector Laboratories, Inc.) was added to the
cells. EdU-positive cells (20 random fields at 40X, >400
cells) were counted. The percentage of proliferation of
control and t-DARPP-expressing cells was determined
by counting EdU-positive cells (green fluorescence) ver-
sus total number of cells, indicated by nuclear DAPI
staining (blue fluorescence).
Gene expression knockdown with small interfering RNA
The HCC-1569 cells were transfected with control
scrambled siRNA (sc-37007) or t-DARPP siRNA (sc-
35173) using siRNA transfection reagent (sc-29528) and
transfection medium (sc-36868) following the manufac-
turer’s instructions (Santa Cruz Biotechnology). The
MCF-7/pcDNA3.1 and MCF-7/t-DARPP cells were
transfected with control scrambled siRNA (#6568; Cell
Signaling Technology) or Akt siRNA I (#6211; Cell Sig-
naling Technology) using RNAifectin transfection
reagent (#G073; abm Applied Biological Materials)
following the manufacturer’s instructions.
Soft agar colony formation assay
Bottom layers of 1 ml 1% noble agar (Difco) in F12
medium, supplemented with 10% FBS, were prepared in
6-well tissue culture plates. Cells (10
5 per well) were
suspended in top layers of 1 ml 0.7% noble agar in F12
medium, supplemented with 10% FBS. Triplicate cul-
tures were established for each cell line. After prepara-
tion of both bottom and top layers, the plates were
placed in a 5% CO2 atmosphere humidified incubator at
37°C. Colonies (≥1 mm) were observed then counted
following approximately 1 month of incubation.
Statistical analysis
The results were expressed as the mean with SD. The
parametric unpaired Student’s t test was used to assess
the difference of growth and proliferation between
MCF-7/pcDNA3.1 and MCF-7/t-DARPP cells. The non-
parametric Mann Whitney test was used to evaluate the
difference of t-DARPP mRNA fold expression of tumors
vs. normal tissue samples and ductal carcinomas vs.
other types of carcinomas. The Fisher Exact test was
used to assess the difference between DARPP-32/
t-DARPP IHC index score and cases (normal vs. tumor),
or histology (IDC vs. other). p < 0.05 was defined as the
statistical significance.
Additional material
Additional file 1: Supplemental Figure S1. t-DARPP expression in
primary breast tumors. A representative immunohistochemical staining
for DARPP-32/t-DARPP of a breast tumor (upper panel) and a matched
adjacent normal tissue (lower panel) samples from a tissue microarray
with C-terminal DARPP-32 antibody. Note that the expression of DARPP-
32/t-DARPP protein(s) is high in tumor tissue as opposed to very low to
absent in adjacent normal tissue, as indicated by dark brown staining.
Additional file 2: Supplemental Table S1. Summary of DARPP-32/t-
DARPP immunostaining from breast tumor microarrays. DARPP-32/t-
DARPP protein(s) expression was assessed by IHC staining on tissue
microarrays containing 59 primary breast tumors and 25 adjacent normal
breast tissue samples using C-terminal DARPP-32 antibody.
Immunohistochemical results were evaluated for intensity and frequency
of staining. The index score of staining was graded as 0 (negative), 1
(weak), 2 (moderate), and 3 (strong). The difference between DARPP-32/t-
DARPP expression frequency and various parameters was assessed by
Fisher Exact Test. IDC, invasive ductal carcinoma.
Additional file 3: Supplemental Table S2. Differential expression of
DARPP-32 and t-DARPP in breast cancer tissues. IHC analysis of
duplicate tissue microarray slides containing 19 primary breast tumor
samples. Immunohistochemical staining was performed with N-terminal
DARPP-32 antibody (EP720Y; abcam) (N-DARPP-32), which exclusively
detects DARPP-32 protein, and C-terminal DARPP-32 antibody (Clone H-
62; Santa Cruz Biotechnology) (C-DARPP-32), which detects both DARPP-
32 and t-DARPP proteins. Both antibodies produced similar strong and
specific staining in positive cases. The results indicated that 8 (42.1%)
tumors exhibited relatively higher t-DARPP expression than DARPP-32, as
shown by stronger immunostaining with C-DARPP-32 than N-DARPP-32.
The relevant IHC scores are depicted in boldface font.
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